Fulcrum Therapeutics, Inc. (FULC)
NASDAQ: FULC · Real-Time Price · USD
10.86
-0.01 (-0.09%)
At close: Feb 12, 2026, 4:00 PM EST
10.72
-0.14 (-1.29%)
Pre-market: Feb 13, 2026, 4:50 AM EST
Fulcrum Therapeutics Revenue
In the year 2024, Fulcrum Therapeutics had annual revenue of $80.00M with 2,752.05% growth.
Revenue (ttm)
$80.00M
Revenue Growth
+2,752.05%
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
45
Market Cap
716.44M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 80.00M | 77.20M | 2,752.05% |
| Dec 31, 2023 | 2.81M | -3.54M | -55.77% |
| Dec 31, 2022 | 6.34M | -12.82M | -66.90% |
| Dec 31, 2021 | 19.16M | 10.34M | 117.19% |
| Dec 31, 2020 | 8.82M | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| MiMedx Group | 393.44M |
| Arvinas | 312.30M |
| Gyre Therapeutics | 107.27M |
| Kura Oncology | 104.03M |
| Upstream Bio | 2.80M |
| KalVista Pharmaceuticals | 1.43M |
| YD Bio | 510.36K |
FULC News
- 6 days ago - Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 4 weeks ago - Fulcrum Therapeutics, Inc. (FULC) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 5 weeks ago - Fulcrum Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 2 months ago - Fulcrum Therapeutics Announces Pricing of Upsized $175.0 Million Public Offering of Common Stock and Pre-Funded Warrants - GlobeNewsWire
- 2 months ago - Fulcrum Therapeutics Announces Proposed $150.0 Million Public Offering of Common Stock - GlobeNewsWire
- 2 months ago - Fulcrum Therapeutics Stock Rally Ignited By Promising Sickle Cell Results - Benzinga
- 2 months ago - Fulcrum Therapeutics, Inc. (FULC) Discusses New Clinical Data From the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease Transcript - Seeking Alpha
- 2 months ago - Fulcrum Therapeutics Announces Positive Initial Results from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease at the 67th American Society of Hematology Annual Meeting - GlobeNewsWire